PKM and non-small cell lung carcinoma: In the same line of evidence, previous studies from our laboratory demonstrated that low PKM2 mRNA levels were associated with better survival rates in NSCLC [17] and low PKM2 expression attained significantly better PFS and OS in SCLC patients treated with platinum-based chemotherapy [16], respectively.